Clinical Trials Browser

Phase 1/2 × Denosumab × 90 days × Clear all

NCT06374459 2026-02-09

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Phase 1/2 Recruiting

Breast Neoplasms